Protocol Ledger

NCT04849390 · Phase II · COMPLETED

A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis

Interventional Phase II clinical trial protocol NCT04849390 sponsored by EsoCap AG in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-29 Enrollment: 43 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04849390
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)43 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04849390
Protocol FieldVerified Registry Value
NCT IdentifierNCT04849390
Consolidated Lead SponsorEsoCap AG
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment43 participants (ACTUAL)
Registered Start Date2021-06-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04849390
Hospital Research SiteLocationSite Profile
Hospital Universitario de La PrincesaMadrid, SpainOpen Hospital Dossier ->
Hospital Universitario Fundación Jiménez DíazMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI